Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5VEN9)

• Drug Name: Minnelide 001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Gastric adenocarcinoma	2B72	Phase 1	[1]
Gastrointestinal cancer	2C11	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DM5VEN9

Molecule-Related Drug Atlas

Drug(s) Targeting Heat shock protein 70 (HSP70)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AG-858	DMNQ5T2	leukaemia	2A60-2B33	Phase 2	[4]
AEG-33773	DMSBLOU	Diabetic neuropathy	8C0Z	Phase 2	[5]
Enkastim-ev	DMGLHYU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
BRX-005	DMTDWIE	Diabetic foot ulcer	BD54	Phase 1	[7]
Minnelide	DMDER9S	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
AG-707	DM7PLMJ	Herpes simplex virus infection	1F00	Phase 1	[9]
H-103	DMRCHOU	Metastatic malignant neoplasm	2D50-2E09	Phase 1	[10]
NK-1001	DMZMQDN	Atrial fibrillation	BC81.3	Discontinued in Phase 2	[11]
Bimoclomol	DMOP95G	Diabetic complication	5A2Y	Discontinued in Phase 2	[12]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Heat shock protein 70 (HSP70)	TTHYBIX	HS71A_HUMAN; HS71B_HUMAN	Modulator	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01927965) Study of Minnelide in Patients With Advanced GI Tumors. U.S. National Institutes of Health.
• [3] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [4] Preparation of a Heat Shock Proteins 70-based Vaccine from DC-tumor fusion cells. Methods Mol Biol. 2011; 787: 255-265.
• [5] Mitogen-activated protein kinase kinase kinase 12 (MAP3K12; DLK); c-jun N-terminal kinase (JNK). SciBX 2(11); doi:10.1038/scibx.2009.462. March 19 2009
• [6] Company report (Multimmune)
• [7] Cardiovascular effects of BRX-005 comparison to bimoclomol. Life Sci. 2000 Aug 25;67(14):1783-9.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine. 2011 Nov 3;29(47):8530-41.
• [10] A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009 Mar;16(3):376-82.
• [11] Novel therapeutic targets in the management of atrial fibrillation. Am J Cardiovasc Drugs. 2014 Dec;14(6):403-21.
• [12] Bimoclomol elevates heat shock protein 70 and cytoprotects rat neonatal cardiomyocytes. Eur J Pharmacol. 2002 Jan 18;435(1):73-7.
• [13] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.